WASHINGTON, D.C. — Patients with hepatitis C virus infection genotype 1
included in the SAPPHIRE-I and II phase 3 clinical trials experienced
few serious adverse events during treatment with direct-acting
antivirals and ribavirin, according to data presented at ICAAC 2014.
Researchers randomly assigned 1,025 patients in a 3:1 ratio to a three
direct-acting antiviral (3D) regimen of ABT-450/ritonavir, ombitasvir
and dasabuvir plus ribavirin (RBV; n=770) or matching placebos (n=255)
for 12 weeks.
The most common adverse events experienced in all groups included
headache and fatigue, followed by nausea, pruritis and insomnia, among